Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.
about
Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analysesModeling Influenza Virus Infection: A Roadmap for Influenza ResearchProtection of young children from influenza through universal vaccination.History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccinesBinding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometryInfluenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccineA heat-inactivated H7N3 vaccine induces cross-reactive cellular immunity in HLA-A2.1 transgenic mice.Differences in pandemic influenza vaccination policies for pregnant women in EuropeIncrease in IFNγ(-)IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza.Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strainsIntralymphatic immunotherapy and vaccination in mice.Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.Intanza (®) 9 µg intradermal seasonal influenza vaccine for adults 18 to 59 years of age.Traditional and new influenza vaccinesVaccine strategies to enhance immune responses in the aged.Influenza vaccines: unmet needs and recent developments.Recent developments with live-attenuated recombinant paramyxovirus vaccines.Fluzone® Intradermal Quadrivalent Influenza Vaccine.Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection.Influenza vaccination in the elderly.Outbreaks of influenza-like illness in long-term care facilities in Winnipeg, Canada.Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in MiceAcceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study.Influenza vaccination in healthcare workers: A comprehensive critical appraisal of the literature.Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).
P2860
Q24614487-E520D406-D3B4-4F74-8E5D-A81C6EAB9C72Q26782421-18C7332C-3910-43AD-A611-E24CF2AE95EEQ27693242-A489271A-AAAA-4EDB-B622-77385ABACCD3Q28079669-84F27011-CB26-4E85-8BA6-33340F7DECDDQ28292279-843FCA74-C50D-4094-9581-D6A758EE22A7Q30353863-72C28FE6-A650-4940-A482-EF8AD0A25369Q30375872-338BAC00-1E10-4763-B665-8106CCBFF5E6Q30386346-48E9B865-7BDA-423F-AB31-0F1BB1E44E7EQ30408457-7F369101-8BB4-414A-AABC-31520E7D103BQ30428685-D65041C2-42CB-424A-A5A6-8FF14C12C8B6Q33655279-313439E7-2BF1-4960-8B93-E27E1B0401C3Q35389863-365FEDCD-708F-4600-A68A-F37031A1E6AAQ35887679-0DB4403B-68AB-4182-8A47-886DC600D3A5Q36447589-6629E22D-242E-40A6-83A6-6B5D035D7B6BQ36887912-AC7F84E8-752B-4310-A086-0238B23819C6Q37035833-48103214-3620-4D73-A3CE-AA21FF30D52CQ37179398-060C5C04-2C2D-4B53-B242-C3602574CD1AQ37518273-35A1A2CF-209D-43A3-B433-63A196D966FDQ38008607-F1A052B0-8DB3-4960-8E92-6F9AD228D037Q38908471-90B37340-467C-4EF7-9DC5-F7DF75A69758Q39079605-5CDF4D3B-DE01-4616-A5BF-8D8ADA6AFB02Q40134515-255C76A9-71B7-447E-9E0D-2ED53A48BB82Q42286840-8EABE599-F1C9-443B-8182-35036C28B67BQ42369088-2DD33B04-6376-45E1-A5B3-5FEBBFBA440BQ45785920-A3F808DF-7FDB-4561-BCC0-81964E3F32B6Q47749933-9D5ABF4E-99AC-4293-A4C0-40070111AB0EQ52619302-5950553D-4C75-41AE-A81B-6C650475B30A
P2860
Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@ast
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@en
type
label
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@ast
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@en
prefLabel
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@ast
Adjuvants and alternative rout ...... f the ideal influenza vaccine.
@en
P2093
P356
P1433
P1476
Adjuvants and alternative rout ...... of the ideal influenza vaccine
@en
P2093
Daniela de Florentis
Filippo Ansaldi
Giancarlo Icardi
Marisa Alberti
Paolo Durando
Rocco Iudici
P356
10.4161/HV.7.0.14560
P478
P577
2011-01-01T00:00:00Z